Arbutus Biopharma (ABUS) Cash & Current Investments (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Cash & Current Investments for 17 consecutive years, with $95.2 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Current Investments fell 15.51% year-over-year to $95.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.2 million (down 15.51% YoY) and the FY2025 annual result came in at $91.5 million, down 25.4% from the prior year.
• Cash & Current Investments grew to $95.2 million in Q1 2026 per ABUS's latest filing, from $91.5 million in the prior quarter.
• Over the last five years, Cash & Current Investments for ABUS reached as high as $165.5 million in Q1 2022 and fell as low as $91.5 million in Q4 2025.
• A 5-year average of $127.6 million and a median of $129.2 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments soared 91.63% — and 2025, when it slumped 30.92%.
• Year by year, Cash & Current Investments stood at $146.9 million in 2022, then decreased by 14.23% to $126.0 million in 2023, then slipped by 2.68% to $122.6 million in 2024, then dropped by 25.4% to $91.5 million in 2025, then advanced by 4.11% to $95.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $95.2 million, $91.5 million, and $93.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.